600201 logo

Jinyu Bio-technology Co., Ltd. Stock Price

SHSE:600201 Community·CN¥12.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

600201 Share Price Performance

CN¥0
-8.56 (-100.00%)
CN¥0
-8.56 (-100.00%)
Price CN¥0

600201 Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards

Jinyu Bio-technology Co., Ltd. Key Details

CN¥1.4b

Revenue

CN¥666.4m

Cost of Revenue

CN¥724.9m

Gross Profit

CN¥620.7m

Other Expenses

CN¥104.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 04, 2026
0.095
52.11%
7.49%
0%
View Full Analysis

About 600201

Founded
1992
Employees
1881
CEO
Jing Zhang
WebsiteView website
www.jinyu.com.cn

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company’s products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vector inactivated, porcine reproductive and respiratory syndrome chimeric virus live and inactivated, and swine fever live, transmissible gastroenteritis in pigs, swine live influenza bivalent, bovine viral diarrhea/mucosal disease, infectious rhinitis two-dose inactivated, brucella gene-deleted live, brucellosis live, inactivated emphysema and gangrene, ruminant disease live, newcastle disease, infectious bursal disease trivalent inactivated, recombinant avian influenza virus trivalent inactivated, infectious bronchitis symptoms, egg drop syndrome type 4 quadrivalent inactivated infectious bronchitis, canine distemper and parvovirus bivalent live, feline panleukopenia calicivirus disease trivalent inactivated trivalent, and inactivated rabies vaccines. Further, the company manufactures and sells biological pharmaceutical preparations, and chemical reagents and auxiliaries; develops biotechnology; transfer and consulting services; advanced medical equipment and instruments; import and export of goods and technology; and provision of property management services. Additionally, it is involved in real estate activities; biochemical products; planting; hotel management services; internet information service finance; biotechnology promotion services; owner-owned house for rent; mechanical equipment processing; investment management; management, meal, technical, and medical services; and trading activities. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.

Recent 600201 News & Updates

Recent updates

No updates